Browse the evidence

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

No association was found with other disorders of the optic nerve or visual pathways.

Other optic nerve or visual pathway disorders are not linked to semaglutide or tirzepatide use.

Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).

Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.

There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.

HU6 may not improve cardiovascular function despite weight loss.

The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.

Awareness of the obesity epidemic is crucial for public health initiatives.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

Up to 40% of adults in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD).

Practitioners should be aware of the high prevalence of MASLD in adult patients.

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.

Ongoing research is crucial to confirm the long-term safety, effectiveness, and clinical role of these agents.

Practitioners should stay updated on research developments regarding these oral agents.

None of the four glucagon-like peptide-1 receptor agonist (GLP-1RA) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA therapies were cost-effective compared with lifestyle management.

Practitioners should consider lifestyle management as the most cost-effective option for treating obesity in this population.